A phase III study of Cemiplimab vs. platinum doublet in patients with first-line non-small cell lung cancer (NSCLC).
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2017
At a glance
- Drugs Cemiplimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Dec 2017 New trial record